Takeda To Start Phase I For Antibody Neuropathic Pain Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical subsidiary Takeda Bio plans to start a domestic Phase I trial for neuropathic pain antibody injection AMG403